Literature DB >> 33121319

SARS-CoV-2 vaccine candidates in rapid development.

Lifeng Li1,2, Pengbo Guo1, Xiaoman Zhang1, Zhidan Yu1, Wancun Zhang1, Huiqing Sun2.   

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading globally. The scientific community is attempting to procure an effective treatment and prevention strategy for COVID-19. A rising number of vaccines for COVID-19 are being developed at an unprecedented speed. Development platforms include traditional inactivated or live attenuated virus vaccines, DNA or RNA vaccines, recombinant viral vector vaccines, and protein or peptide subunit vaccines. There are 23 vaccines in the clinical evaluation stage and at least 140 candidate vaccines in preclinical evaluation. In this review, we describe research regarding basic knowledge on the virus, updates on the animal models, current landscape of vaccines in clinical evaluation and updated research results on vaccine development. Safe and effective COVID-19 vaccines require further investigation.

Entities:  

Keywords:  COVID-19 pandemic; SARS-CoV-2; animal models; coronavirus; vaccine development

Mesh:

Substances:

Year:  2020        PMID: 33121319      PMCID: PMC7993188          DOI: 10.1080/21645515.2020.1804777

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  56 in total

1.  Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.

Authors:  Kangpeng Xiao; Junqiong Zhai; Yaoyu Feng; Niu Zhou; Xu Zhang; Jie-Jian Zou; Na Li; Yaqiong Guo; Xiaobing Li; Xuejuan Shen; Zhipeng Zhang; Fanfan Shu; Wanyi Huang; Yu Li; Ziding Zhang; Rui-Ai Chen; Ya-Jiang Wu; Shi-Ming Peng; Mian Huang; Wei-Jun Xie; Qin-Hui Cai; Fang-Hui Hou; Wu Chen; Lihua Xiao; Yongyi Shen
Journal:  Nature       Date:  2020-05-07       Impact factor: 49.962

2.  Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.

Authors:  Jiang-Tao Lin; Jian-San Zhang; Nan Su; Jian-Guo Xu; Nan Wang; Jiang-Ting Chen; Xin Chen; Yu-Xuan Liu; Hong Gao; Yu-Ping Jia; Yan Liu; Rui-Hua Sun; Xu Wang; Dong-Zheng Yu; Rong Hai; Qiang Gao; Ye Ning; Hong-Xia Wang; Ma-Chao Li; Biao Kan; Guan-Mu Dong; Qi An; Ying-Qun Wang; Jun Han; Chuan Qin; Wei-Dong Yin; Xiao-Ping Dongs
Journal:  Antivir Ther       Date:  2007

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

5.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.

Authors:  Julie E Martin; Mark K Louder; LaSonji A Holman; Ingelise J Gordon; Mary E Enama; Brenda D Larkin; Charla A Andrews; Leatrice Vogel; Richard A Koup; Mario Roederer; Robert T Bailer; Phillip L Gomez; Martha Nason; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  Vaccine       Date:  2008-09-26       Impact factor: 3.641

Review 6.  Progress and Prospects on Vaccine Development against SARS-CoV-2.

Authors:  Jinyong Zhang; Hao Zeng; Jiang Gu; Haibo Li; Lixin Zheng; Quanming Zou
Journal:  Vaccines (Basel)       Date:  2020-03-29

7.  A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.

Authors:  Yong-Zhen Zhang; Edward C Holmes
Journal:  Cell       Date:  2020-03-26       Impact factor: 41.582

8.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2.

Authors:  Jianzhong Shi; Zhiyuan Wen; Gongxun Zhong; Huanliang Yang; Chong Wang; Baoying Huang; Renqiang Liu; Xijun He; Lei Shuai; Ziruo Sun; Yubo Zhao; Peipei Liu; Libin Liang; Pengfei Cui; Jinliang Wang; Xianfeng Zhang; Yuntao Guan; Wenjie Tan; Guizhen Wu; Hualan Chen; Zhigao Bu
Journal:  Science       Date:  2020-04-08       Impact factor: 47.728

9.  COVID-19: Knowns, Unknowns, and Questions.

Authors:  Stuart Weston; Matthew B Frieman
Journal:  mSphere       Date:  2020-03-18       Impact factor: 4.389

10.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

Authors:  Neeltje van Doremalen; Teresa Lambe; Alexandra Spencer; Sandra Belij-Rammerstorfer; Jyothi N Purushotham; Julia R Port; Victoria A Avanzato; Trenton Bushmaker; Amy Flaxman; Marta Ulaszewska; Friederike Feldmann; Elizabeth R Allen; Hannah Sharpe; Jonathan Schulz; Myndi Holbrook; Atsushi Okumura; Kimberly Meade-White; Lizzette Pérez-Pérez; Nick J Edwards; Daniel Wright; Cameron Bissett; Ciaran Gilbride; Brandi N Williamson; Rebecca Rosenke; Dan Long; Alka Ishwarbhai; Reshma Kailath; Louisa Rose; Susan Morris; Claire Powers; Jamie Lovaglio; Patrick W Hanley; Dana Scott; Greg Saturday; Emmie de Wit; Sarah C Gilbert; Vincent J Munster
Journal:  Nature       Date:  2020-07-30       Impact factor: 49.962

View more
  12 in total

Review 1.  Perspectives on RNA Vaccine Candidates for COVID-19.

Authors:  Pobitra Borah; Pran Kishore Deb; Nizar A Al-Shar'i; Lina A Dahabiyeh; Katharigatta N Venugopala; Vinayak Singh; Pottathil Shinu; Snawar Hussain; Satyendra Deka; Balakumar Chandrasekaran; Da'san M M Jaradat
Journal:  Front Mol Biosci       Date:  2021-03-25

2.  Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice.

Authors:  Juan Shi; Xiaoxiao Jin; Yan Ding; Xiaotao Liu; Anran Shen; Yandan Wu; Min Peng; Chuanlai Shen
Journal:  Vaccines (Basel)       Date:  2021-11-24

3.  Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.

Authors:  Itay Lotan; Mark A Hellmann; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Adi Wilf-Yarkoni
Journal:  Neuromuscul Disord       Date:  2022-02-05       Impact factor: 4.296

4.  Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study.

Authors:  Giancarlo Ripabelli; Manuela Tamburro; Nicandro Buccieri; Carmen Adesso; Valeria Caggiano; Fabio Cannizzaro; Michela Anna Di Palma; Gloria Mantuano; Valeria Giovanna Montemitro; Anna Natale; Leonardo Rodio; Michela Lucia Sammarco
Journal:  J Community Health       Date:  2021-10-09

5.  [Cutaneous vasculitis due to COVID-19 vaccination].

Authors:  Elena María Gázquez Aguilera; Manuel Rodríguez García; María Teresa Cantón Yebra
Journal:  Med Clin (Barc)       Date:  2021-11-13       Impact factor: 3.200

Review 6.  Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.

Authors:  Josephine Wambani; Patrick Okoth
Journal:  Egypt J Intern Med       Date:  2022-03-26

Review 7.  A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic.

Authors:  Rashed Noor
Journal:  Bull Natl Res Cent       Date:  2022-02-16

8.  Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors.

Authors:  Shafi Mahmud; Suvro Biswas; Gobindo Kumar Paul; Mohasana Akter Mita; Maria Meha Promi; Shamima Afrose; Md Robiul Hasan; Shahriar Zaman; Md Salah Uddin; Kuldeep Dhama; Talha Bin Emran; Md Abu Saleh; Jesus Simal-Gandara
Journal:  Biology (Basel)       Date:  2021-06-26

9.  A Postoperative Man with Marfan Syndrome with Palpitations and Chest Pain After Receiving the SARS-CoV-2 Vaccine.

Authors:  Kun Li; Bin Huang; Tao Ji; Shao-Gan Xu; Wen Jiang
Journal:  Infect Drug Resist       Date:  2021-07-27       Impact factor: 4.003

10.  Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.

Authors:  Itay Lotan; Adi Wilf-Yarkoni; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Mark A Hellmann
Journal:  Eur J Neurol       Date:  2021-08-02       Impact factor: 6.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.